IWK Health Centre Standardizes to Masimo SET® Pulse Oximetry

IRVINE, Calif., Nov. 27, 2012 /PRNewswire/ -- Masimo (NASDAQ: MASI) today announced that the IWK Heath Centre, Atlantic Canada's  leading health centre providing specialized, quality care to women, children, youth and families, has converted  to Masimo SET^® pulse oximetry and sensor technologies, the standard-of-care at leading health organizations worldwide.

Masimo SET^® pulse oximetry virtually eliminates false alarms¹ and increases a clinician's ability to detect life-threatening events² – helping to substantially contribute to improved patient outcomes and patient safety. Masimo SET^® pulse oximetry also has been shown to help clinicians reduce retinopathy of prematurity³, screen for critical congenital heart disease in newborns⁴, and save lives in post-surgical floors, recovery², labor and delivery rooms⁵, and  ICUs⁶.

IWK's conversion to Masimo SET^® pulse oximetry is in keeping with the IWK's dedication to excellence in care and delivering the best possible results for its patients. More than 100 independent clinical studies have confirmed that Masimo SET^® technology allows clinicians to accurately monitor blood oxygen saturation in the most challenging conditions, including patient movement and low peripheral perfusion.

"Specializing in Children's and Women's Health, it is vital that we use the technology that provides our patients and staff with a consistent and accurate measure of blood oxygen saturation levels," said David Hancock, Technology Assessment Officer, IWK Health Centre. "We have standardized on Masimo technology in our ICUs, ORs and inpatient care areas for all patient monitoring, which will lead to improved patient outcomes."

The Health Centre also has the option to upgrade at any time to Masimo rainbow^® Pulse CO-Oximetry™, which allows clinicians to noninvasively monitor multiple blood constituents that previously required invasive or complicated procedures, including total hemoglobin (SpHb^®), oxygen content (SpOC™), carboxyhemoglobin (SpCO^®), methemoglobin (SpMet^®), Pleth Variability Index (PVI^®), and acoustic respiration rate (RRa™).

"We are happy to have forged this great partnership with the IWK, which like other leading healthcare organizations is demonstrating its commitment to patient safety and care by taking advantage of our breakthrough measure-through motion and low perfusion pulse oximetry technology," said Masimo founder and CEO Joe Kiani. "We value this relationship with IWK, and together look forward to helping their skilled and dedicated staff meet and exceed their patient-care needs."

¹ Shah N, Ragaswamy H, Govindugari K, Estanol L. "Performance of three new-generation pulse oximeters during motion and low perfusion in volunteers." Journal of Clinical Anesthesia. 2012 (10.1016/j.jclinane.2011.10.012) Available online here
² Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology, February 2010, Vol. 112, Issue 2. Available online here  
³ Chow L.C., Wright K.W., Sola A.; CSMC Oxygen Administration Study Group. "Can Changes in Clinical Practice Decrease the Incidence of Severe Retinopathy of Prematurity in Very Low Birth Weight Infants?" Pediatrics. 2003 Feb;111(2):339-45. 
⁴ de Wahl Granelli A, Wennergren M, Sandberg K, et al. Impact of pulse oximetry screening on detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ 2009; 338: a3037. 
⁵ Baquero H, Alviz R, Castillo A, Neira F, Sola A. "Avoiding Hyperoxemia During Neonatal Resuscitation: Time To Response Of Different SpO2 Monitors." Acta Paed April 2011 Vol. 100, Issue 4, pp 515-518. Published online here
⁶  Goldstein MR, Martin GI, Sindel BD, Furman GI, Ochikubo C, Yand L. SatSeconds Alarm Management Misses Short Desaturations Common to Periodic Breathing and Infantile Apnea. Pediatric Research 2001;49(4):400A/2296.

About the IWK Health Centre
The IWK Health Centre is Atlantic Canada's leading health centre providing specialized, quality care to women, children, youth and families in the Maritimes and beyond. In addition to providing highly specialized (tertiary) care, the IWK also provides primary care services. The IWK is also engaged in leading-edge research; works to promote healthy lifestyles for families; and as an academic health centre provides education opportunities for health professionals and other learners. Visit www.iwk.nshealth.ca for more information.

About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET^®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET^® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET^® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb^®), oxygen content (SpOC^TM), carboxyhemoglobin (SpCO^®), methemoglobin (SpMet^®), and Pleth Variability Index (PVI^®), in addition to SpO₂, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including: total hemoglobin (SpHb), SpCO, SpMet, PVI, and RRa contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN is under license from University HealthSystem Consortium.

SOURCE Masimo

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED